近十年来，抗体药物复合物（ADCs）在包括乳腺癌在内的实体肿瘤中蓬勃发展。 ADCs结合了单克隆抗体的专属性和细胞毒性药物的强效性，能够通过施加特殊的旁观效应，将细胞毒素直接传递到表达异质抗原的肿瘤细胞及其周围的协同反应者。截至目前，有三种ADCs（T-DM1，T-DXd和SG）已获批正式上市并在乳腺癌的临床实践中得到应用，许多有前途的产品仍在研发中。作为一种前所未有的乳腺癌亚型，在实现固化药物疗效之后，以往认为缺乏明确靶点和有效疗法的HER2-低人群的认知和治疗范式已经被ADCs彻底改写，并在正在进行的试验中取得了一些令人鼓舞的成就。在此，我们将讨论HER2过度表达和HER2-低乳腺癌中ADCs的构思知识，最新进展和未来视角。版权所有 © 2022 Elsevier B.V.。保留所有权利。

The recent decade has witnessed a vigorous prosper of antibody-drug conjugates (ADCs) in solid tumors including breast cancer. Integrating the specificity of monoclonal antibodies and potency of cytotoxic drugs, ADCs are capable of delivering cytotoxic agents directly to tumor cells and surrounding accomplices with heterogeneous antigen expression by exerting the distinctive bystander effect. Up till now, three ADCs (T-DM1, T-DXd and SG) have attained the official approval and stepped into clinical practices in breast cancer, with numerous promising products in the pipeline. As an unprecedented breast cancer subgroup identified following solidified drug benefit, the cognitive and therapeutic paradigm of HER2-low population which was previously thought lacking definite targets and efficacious regimens has been thoroughly rewritten by ADCs, and several encouraging achievements are expected in ongoing trials. Herein, we discuss the contrived knowledge, latest advancements and future perspectives of ADCs in HER2-overexpressing and HER2-low breast cancer.Copyright © 2022 Elsevier B.V. All rights reserved.